Waverley Pharma Inc. (FRA:5GZ)

Germany · Delayed Price · Currency is EUR

0.0040

0.00 (0.00%)

Last updated: Oct 21, 2026, 2:47 PM CEST

Market Cap	338.00K -48.9%
Revenue (ttm)	723.78K -6.2%
Net Income	-458.85K
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0040
Previous Close	0.0040
Day's Range	0.0040 - 0.0040
52-Week Range	0.0040 - 0.0120
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 27, 2026

About Waverley Pharma

Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. The company develops PARP-1 Inhibitors for cancer treatment. It also operates a retail pharmacy in the United States. In addition, it is involved in the sale of prescription medications, over-the-counter products, and associated pharmacy services. Waverley Pharma Inc. was founded in 2014 and is headquartered in Winnipeg, Canada. [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2014

Country Canada

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 5GZ

Financial Performance

In 2025, Waverley Pharma's revenue was 1.35 million, an increase of 183.90% compared to the previous year's 475,373. Losses were -499,214, -47.29% less than in 2024.

Financial numbers in CAD Financial Statements